Results 131 to 140 of about 4,600,401 (406)

Anticoagulant therapy and its impact on dental patients: a review.

open access: yesAustralian dental journal, 2016
Several new oral anticoagulants have been studied in the past decade, and have now started to enter the market. These drugs are reported to be as effective as, or more effective than, warfarin.
D. Thean, Mario Alberghini
semanticscholar   +1 more source

Single Test‐Based Diagnosis and Subtyping of Pulmonary Hypertension Caused by Fibrosing Mediastinitis Using Plasma Metabolic Analysis

open access: yesAdvanced Science, EarlyView.
Pulmonary hypertension caused by fibrosing mediastinitis has a five‐year survival rate of just 56%. Current diagnostic approaches are complex for patients with mobility limitations and can lead to misdiagnoses due to their nonspecific clinical features.
Yating Zhao   +17 more
wiley   +1 more source

KK2DP7 Stimulates CD11b+ Cell Populations in the Spleen to Elicit Trained Immunity for Anti‐Tumor Therapy

open access: yesAdvanced Science, EarlyView.
This study introduces KK2DP7, a dendrimer‐structured peptide adjuvant, as a tool to decode trained immunity's role in antitumor therapy. Splenic CD11b+ cells mediate tumor suppression via TLR2‐IRF7 activation and epigenetic reprogramming, validated by adoptive transfer experiments.
Rui Zhang   +5 more
wiley   +1 more source

Engineered Genetic Circuits Activated by Bezafibrate Improve ESC‐Based TAA Cancer Vaccine Efficacy and PD‐L1 Nanobody Therapy

open access: yesAdvanced Science, EarlyView.
Synthetic gene circuits regulated by bezafibrate are developed to express tumor antigens and PD‐L1 nanobody (PD‐L1nb), enhancing cancer immunotherapy. Delivered via HEK293T cells, ESCs, or directly injected the plasmids containing the circuit into the tumor, the circuits reduce tumor growth, boost CD8+ T cells, and minimize T cell exhaustion.
Meiling Jin   +3 more
wiley   +1 more source

QT and Tpeak‐Tend interval variability: Predictive electrical markers of hospital stay length and mortality in acute decompensated heart failure. Preliminary data

open access: yesClinical Cardiology, Volume 45, Issue 12, Page 1192-1198, December 2022., 2022
Abstract Background As previously reported, an increased repolarization temporal imbalance induces a higher risk of total/cardiovascular mortality. Hypothesis The aim of this study was to assess if the electrocardiographic short period markers of repolarization temporal dispersion could be predictive of the hospital stay length and mortality in ...
Gianfranco Piccirillo   +11 more
wiley   +1 more source

A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents.

open access: yesNew England Journal of Medicine, 1996
BACKGROUND The clinical benefit of coronary-artery stenting performed in conjunction with coronary angioplasty is limited by the risk of thrombotic occlusion of the stent as well as hemorrhagic and vascular complications of intensive anticoagulation.
A. Schömig   +11 more
semanticscholar   +1 more source

Meta-analysis of postoperative antithrombotic therapy after left atrial appendage occlusion

open access: yesJournal of International Medical Research, 2020
Objective This meta-analysis explored the safety and effectiveness of different anticoagulant regimens after left atrial appendage occlusion (LAAO). Methods Databases, such as PubMed, MEDLINE, EMBASE, Web of Science, and Cochrane Library, were searched ...
Shu-yue Li   +5 more
doaj   +1 more source

Identification of CD38high Monocyte as a Candidate Diagnostic Biomarker and Therapeutic Target for Sepsis

open access: yesAdvanced Science, EarlyView.
This study uncovers that CD38high monocytes discriminate sepsis and sterile inflammation and are associated with 28‐day mortality in bacterial sepsis. Targeting CD38 therapy reduces inflammatory response in monocytes and in sepsis mice model. Mechanistically, CD38‐HIF‐1α/glycolysis/MGO loop exacerbates sepsis‐induced immune dysregulation.
Ning Hua   +19 more
wiley   +1 more source

Long‐term outcome prediction for chronic thromboembolic pulmonary hypertension after pulmonary endarterectomy

open access: yesClinical Cardiology, Volume 45, Issue 12, Page 1255-1263, December 2022., 2022
Abstract Background The definitive treatment for chronic thromboembolic pulmonary hypertension (CTEPH) is pulmonary endarterectomy (PEA), which has good long‐term outcomes. However, after surgery, a quarter of the patients still have residual pulmonary hypertension (RPH). In pulmonary hemodynamics, there are no unified criteria for RPH, even though the
Wu Song   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy